Athanor Capital, LP Glycomimetics Inc Transaction History

Athanor Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $128,963 - $203,274	-47,942 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $72,040 - $117,330	-23,466 Reduced 32.86%	47,942 $147,000
Q2 2020 Aug 13, 2020	BUY	$2.06 - $3.76 $82,422 - $150,441	40,011 Added 127.44%	71,408 $268,000
Q1 2020 May 14, 2020	SELL	$1.83 - $5.41 $51,560 - $152,426	-28,175 Reduced 47.3%	31,397 $72,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $240,075 - $387,218	59,572 New	59,572 $315,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.